Abstract
Objectives: Patients with cystic fibrosis are at increased risk for electrolyte abnormalities and this problem extends beyond early age. The aim of this study is to evaluate the incidence of sodium depletion in children treated with ivacafor/tezacaftor/elexaftor (IVA/TEZ/ELEX) and establish if there is a change in sodium balance compared to pre-modulator state.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
